Rob Fannon

NImmune Biopharma, Inc’s Founder, Executive Chairman & CEO Josep B. was recently honored as a Virginia Success Story at THRiVE, Virginia Bio’s largest conference of the year. Dr. Bassaganya-Riera described his role in building a thriving biotech innovation ecosystem from the ground up, encompassing NImmune Biopharma, The NIMML Institute, and BioTherapeutics Inc., alongside Landos Biopharma, Inc., which was recently acquired by AbbVie. He underscored the groundbreaking potential of NImmune’s therapeutics in addressing the unmet clinical needs of millions of patients suffering from autoimmune diseases worldwide. NImmune’s lead drug, omilancor, is a first-in-class, best-in-class, oral, once-daily therapeutic in Phase 3 clinical development with a planned NDA filing for Ulcerative Colitis by 2026 and in Phase 2 clinical development for Crohn’s disease. Additionally, NIM-1324, a first-in-class, oral, once-daily, systemically distributed LANCL2 agonist, is in Phase 2 clinical development for the treatment of systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis and other undisclosed indications. Watch Dr. Bassaganya-Riera’s full remarks below. ? #VirginiaBio #THRiVE #PrecisionMedicine #LANCL2

25

3 条评论

Innovation starts here. For sponsors looking to make a real impact, #GeneTherapies are promising. Pharmacokinetic analysis can shape dosing strategies and provide input into drug safety & efficacy – learn more: https://bit.ly/3zDqPRs #CGT #GeneTherapy #PKassessments

17

If you missed our poster presentation at #ASCO24 titled "Feasibility and Utilization of Electronic Patient-Reported Outcome Measures for Lung Cancer in Routine Clinical Care," in collaboration with our partners at the University of North Carolina and Takeda Pharmaceuticals, below are the key findings. ? This study explored the feasibility of standardizing PRO measures among patients with lung cancer in US clinical practice. Using the ePRO and alerts data collected from Carevive RSM, we explored patient engagement, measured by survey compliance and data completeness, as well as clinical team engagement measured by the platform utilization time, time to alert response, and clinical action taken when patients reported moderate/severe symptoms (Figures 2 and 4). ? Results support the feasibility of integrating a standard set of multi-domain ePRO measures, comparable in breadth and scope to the Health Outcomes Observatory (H2O) Core Outcomes Set, into routine lung cancer care. ? Patient engagement was high, as indicated by survey compliance and completeness, particularly in the first 5 weeks of enrollment. The median survey follow-up was 8 weeks, with 85% median compliance over that time. ? The clinical team's engagement was high, as indicated by frequent usage of the platform and timely response to symptom alerts, with a median of 20 hours and 69.3% addressed in less than 2 days. ? Findings support the value of remote symptom alerts, when integrated into clinical workflow, for enhancing the timeliness of patient and care team communications, and timely addressing of symptoms to optimize care. Read more of the presentation here: https://lnkd.in/esFXwb69 Aaron Galaznik Emelly Rusli Keri Collette Mordecai Kramer Bruno Lempernesse #carevive?#digitaloncology?#cancer?#cancercare?#oncology?#patientreportedoutcomes?#oncologydata?#clinicalinnovation?#drugcommercialization?#RWD?#RWE?#smartdata

2

Tomorrow kicks off the American Society of Clinical Oncology (ASCO) Annual Meeting, where professionals working in #Oncology spend time connecting and collaborating. Find Corcept at Booth #14157 to learn more about the potential role of our proprietary selective #CortisolModulator in platinum-resistant ovarian cancer. #ASCO24 #OvarianCancer #ClinicalResearch #Phase3

105

?? Check out the Mendelspod podcast episode, "Two Industry Leaders on Dealing with the Growing Complexity of Genomic Cancer Data," featuring JAX's Cara Statz & Illumina's Erica Schnettler discussing the landscape of oncology research, oncology testing and variant interpretation:

2

ClinGen Resource's patient registry, GenomeConnect, is at Virginia State Genetics Education Conference #VAAGC. Stop by our booth today to learn more about engaging patients in data sharing. #GCChat #Genetics #DataSharing.

9

?? Exciting updates from ASCO 2024! Our colleagues Emily Viglianco, MS, MPH, and Sara M. Schmitt, PhD, have penned an insightful blog on the latest in oncology treatment innovations. ?? The conference highlighted thrilling progress in the expansion of existing therapies. Notably, CDK4/6 and PI3K inhibitors, traditionally used in breast cancer, are now being explored for a variety of solid tumors, including colorectal and prostate cancers. This adaptation promises to enhance treatment efficacy across different cancer types. ?? CAR-T cell therapies and immune checkpoint inhibitors are also breaking new ground. Their expansion into solid tumors and combination strategies are showing promising results, potentially revolutionizing treatment paradigms. ?? Personalized medicine continues to drive advancements, with genomic profiling playing a pivotal role in tailoring therapies to individual patient needs, enhancing outcomes while reducing side effects. ?? The push for precision medicine is redefining oncology, with tumor-agnostic approaches and innovative vaccine applications opening new avenues for prevention and treatment. Stay tuned for more updates on these transformative developments in cancer care. Let's continue to support research and collaboration that leads to more precise and effective treatments for patients worldwide. Check out the full blog: https://lnkd.in/gG5rf66T

16

1 条评论

Join Taylor Lipsich from PatientWing as she explores 'How Building Trust with Rare Disease Patients Accelerates Trial Enrollment' at the 20th Biopharma Clinical Trials Nexus in San Diego. Don't miss this insightful discussion! #NEXUSconference #Patientwing #BioPharmaNexus #raredisease

41

4 条评论

What does it mean to extend the value of model-informed drug development (MIDD) beyond clinical trials and regulatory approval? Certara's Ananth Kadambi and Patrick Smith collaborated with Regeneron's Mohamed Kamal and Samit Ganguly on a recent publication that highlights how integrated modeling approaches can provide considerable value post approval by: ? Allowing for earlier strategic preparation for required discussions with payers and HTAs around reimbursement of newly approved assets than generally thought possible ? Helping identify data gaps that can be managed by focus data collection during pivotal clinical trials or designing real-word data collection studies ? Lowering drug development costs by informing early "no-go" decisions if an asset in early development is found to have limited economic potential Congratulations to our authors. You can read the full article here: https://ow.ly/sOF150SCH1h Read more on this topic: https://ow.ly/LA2J50SCH1f #drugdevelopment #MIDD #clinicaltrials #clinicalpharmacology #marketaccess #reimbursement #realworlddata

32

1 条评论

In case you missed it, this Citeline article by Dexter Yan highlighted our #genetherapy candidates for Bietti's Crystalline Dystrophy and phenylketonuria (PKU). Both have received IND approval and #orphandrug designation by the FDA. Read more about our innovative pipeline here: https://bit.ly/3WYT3U0

8

89% of cancer centers in the U.S. are reporting shortages of one or more of the more commonly used oncology drugs. While the shortages are nothing new, they are continuing to prevent patients from receiving the help and care they need in the more trying time of their lives. As providers, it's our job to figure out new treatments, therapies, and opportunities that can replace these drugs (at respectable costs), bringing back accessibility to the field of oncology. #Oncology #DrugShortages #SupplyChain #FutureOfHealthcare

2

Bristol Myers Squibb has queued a Phase 1 study of Orum Therapeutics’ ORM-6151 (BMS-986497), a first-in-class, anti-CD33 antibody-enabled GSPT1 degrader for the treatment of patients with acute myeloid leukemia or high-risk myelodysplastic syndromes. The study will enroll an estimated 35 patients and is due to start in late May 2024. Orum Therapeutics has developed a new class of ADC payloads, called neoDegraders, to specifically degrade intracellular target proteins within cancer cells via the E3 ubiquitin ligase pathway. Conjugated to antibodies, neoDegraders are designed to be delivered specifically to cancer cells and degrade the intracellular target protein and cause tumor cell death. https://lnkd.in/edTcDRFj

32

Learn how to critically evaluate processing strategies for lentiviral vectors while considering titer and purity characteristics at ESACT. Join Harm Niederlaender from Sartorius as he shares his thoughts during our sponsored pre-conference symposium on June 23 at 1:30 pm. https://sar.to/nawzm #SimplifyingProgress #InThisTogether #AdvancedTherapies #CellandGeneTherapy #ESACT #ESACT2024

45

1 条评论

Last week on The Genetics Podcast, Sano CEO Patrick Short sat down with Lori Orlando, Director of the Precision Medicine Program at the Center for Applied Genomics and Precision Medicine at Duke University, to discuss how family history and genetic data can transform healthcare. ??????????? Lori shared insights from her groundbreaking studies and outlined both the challenges and opportunities of integrating genetics into primary care. Check out a recap or listen in full.?? https://lnkd.in/e9tuders #Genomics #PrecisionMedicine

8

?? Exciting News! ?? We are thrilled to share that our CEO & Co-Founder, LakshmiDevi Ethirajan, will be moderating a panel at the 20th BioPharma Nexus Conference in San Diego. The panel discussion will focus on "Advancing Hit Discovery for Complex and Emerging Targets. Join us in San Diego on May 8-9 to gain insights from industry leaders and see how innovations are shaping the future of #DrugDiscovery!

15

2 条评论

#CARTcelltherapy offers needed treatment options for rare diseases. In light of recent #FDA approvals (https://lnkd.in/ee8pv7BN), learn how Judi by AG Mednet supported a prominent clinical-stage #biotech on a pivotal Phase 2 CAR-T #oncology trial using our Judi for Eligibility and Judi for Adjudication solutions.

9